|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifamib in children and adolescents with refractory leukemias:a report from the Children's Ontology Group 显示文摘 | Widemann BC Arceci RJ Jayaprakash N | 2011 | Pediatr Blood Cancer2011，56，2： | 1 |
| 2 | Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: a report from the Children's Oncology Group 显示文摘 | Kim A Widemann BC Krailo M | 2015 | Pediatr Blood Cancer2015，62，9： | 1 |
| 3 | Phase 1 trial and pharmaco- kinetic study of arsenic trioxide in children and adolescents with refrac- tory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma显示文摘 | Fox E Razzouk BI Widemann BC | 2008 | Blood2008，111，2： | 1 |
| 4 | Pharmaco-kinetics and metabolism of the methotrexate metabolite 2,4-diamino-N(10)-methylpteroic acid显示文摘 | Widemann BC Sung E Anderson L | 2000 | J Pharmacol Exp Ther2000，294，3： | 1 |
| 5 | PET-guided biopsy with needle navigation facilitates diagnosis of angiosarcoma in neurofibromatosis type1显示文摘 | Koethe Y Widemann BC Hajjar F | 2013 | Pediatr Blood Cancer2013，60，12： | 1 |
| 6 | Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma 显示文摘 | Fox E Razzouk BI Widemann BC | 2008 | Blood2008，111，2： | 1 |
| 7 | Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma显示文摘 | Fox E Razzouk BI Widemann BC | 2008 | Blood2008，111，2： | 1 |
| 8 | Understanding and managing methotrexate nephrotoxicity 显示文摘 | Widemann BC Adamson PC | 2006 | Oncologist2006，11，6： | 1 |
| 9 | Pharmacokinetics and metabolism of the methotrexate metabolite 2,4-diamino-N(10)-methylpteroic acid显示文摘 | Widemann BC Sung E Anderson L | 2000 | J Pharmacol Exp Ther2000，294，3： | 1 |
| 10 | Efficacy of glucarpidase(carboxypeptidase g2)in patients w ith acute kidney injury after high-dose methotrexate therapy显示文摘 | Widemann BC Schwartz S Jayaprakash N | 2014 | Pharmacotherapy2014，34，5： | 1 |
| 11 | Carboxypeptidase-G2,thymidine,and leucovorin rescue in cancer patients w ith methotrexate-induced renal dysfunction显示文摘 | Widemann BC Balis FM Murphy RF | 1997 | J Clin Oncol1997，15，5： | 1 |
| 12 | Glucarpidase,leucovorin,and thymidine for high-dose methotrexate-induced renal dysfunction:clinical and pharmacologic factors affecting outcome显示文摘 | Widemann BC Balis FM Kim A | 2010 | J Clin Oncol2010，28，25： | 1 |
| 13 | Using a lower dose of glucarpidase to reduce plasma levels of methotrexate显示文摘 | Widemann BC | 2013 | Clin Adv Hematol Oncol2013，11，5： | 1 |
| 14 | Efficacy ofglucarpidase ( Carboxypeptidase g2 ) in patients with acute kidney injury after high-dose methotrexate therapy 显示文摘 | Widemann BC Schwartz S Jayaprakash N | 2014 | Pharrnacotherapy2014，34，5： | 1 |
| 15 | Efficacy of Gluca- rpidase( Carboxypeptidase G2) in patients with acute kidney inju- ry after high-dose methotrexate therapy 显示文摘 | Widemann BC Schwartz S Jayaprakash N | 2014 | Pharmacotherapy2014，34，5： | 1 |
| 16 | High-Dose Methotrexate-Indueed Nephrotoxicity in Patients with Osteo- sarcoma显示文摘 | Widemann BC Balis FM Kempf-Bielack B | 2004 | Cancer2004，100，： | 1 |
| 17 | Practical considerations for the administration of glucarpidase in high-dose methotrexate(HDM TX)induced renal dysfunction显示文摘 | Widemann BC | 2015 | Pediatr Blood Cancer2015，62，9： | 1 |
| 18 | Understanding and managing methotrexate nephrotoxicity显示文摘 | Widemann BC Adamson PC | 2006 | Oncologist2006，11，6： | 1 |
| 19 | High-dose methotrexate-induced nephrotoxicity in patients withosteosarcoma显示文摘 | WIDEMANN BC BALIS FM KEMPF-BIELACK B | 2004 | Cancer2004，100，10： | 1 |
| 20 | Carboxypeptid- ase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction显示文摘 | Widemann BC Balls FM Murphy RF | 1997 | J Clin Oncol1997，15，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员